

# Zirconium-89 Trastuzumab tracer uptake in metastatic breast cancer: A pilot study.

Published: 30-09-2014

Last updated: 21-04-2024

Primary Objectives: Use <sup>89</sup>Zr-Trastuzumab to characterise the in vivo biodistribution using PET imaging in the primary tumour and distant metastases. Compare the uptake in patients with Her2/neu positive breast cancer to patients with HER2/neu...

|                              |                                                          |
|------------------------------|----------------------------------------------------------|
| <b>Ethical review</b>        | Approved WMO                                             |
| <b>Status</b>                | Pending                                                  |
| <b>Health condition type</b> | Breast neoplasms malignant and unspecified (incl nipple) |
| <b>Study type</b>            | Observational invasive                                   |

## Summary

### ID

NL-OMON41895

### Source

ToetsingOnline

### Brief title

Zirconium-89 Trastuzumab tracer for metastatic breast cancer patients

### Condition

- Breast neoplasms malignant and unspecified (incl nipple)

### Synonym

HER2 positive or -negative metastatic breast cancer

### Research involving

Human

### Sponsors and support

**Primary sponsor:** Antoni van Leeuwenhoek Ziekenhuis

**Source(s) of monetary or material Support:** Afdeling Nucleaire Geneeskunde;NKI-AVL

## Intervention

**Keyword:** Breast cancer, HER2/neu, PET/CT, Zirconium

## Outcome measures

### Primary outcome

Describe and quantify the <sup>89</sup>Zirconium-Trastuzumab biodistribution in all patients in terms of dose per volume (MBq/ml), percentage of injected dose per volume tissue (%ID/ml) and Standardised Uptake Values (SUVs) based on the PET/CT. This work will provide an insight into the tracer accumulation in malignant and normal tissues with respect to mean accumulation and the variation in accumulation patterns. Hence, this project will be used as a pilot for a future larger study or, depending on the results, may serve as a validation for the clinical application of this technique.

### Secondary outcome

A description of the relation between uptake patterns on <sup>18</sup>F-FDG and <sup>89</sup>Zr-Trastuzumab PET/CT will be provided. Additionally, the variation serum HER2 and Trastuzumab concentrations will be related to the Zr-89 Trastuzumab accumulation in the normal liver tissue and tumour lesions. These data again will provide mean and variation values in Her2/neu positive and negative tumours.

## Study description

### Background summary

For patients with HER2/neu overexpressing or amplified breast cancer, Trastuzumab is the most important key of treatment. If we can visualise the amount

of 90-Zirconium-Trastuzumab tracer that binds the primary tumour, we could in the future possibly predict the effectiveness of Trastuzumab therapy.

If distant metastases are present, the Trastuzumab therapy is meant to bind to all the lesions to achieve an optimal treatment. The problem exists that commonly used diagnostic modalities cannot discriminate between different primary tumour or metastasis subtypes without a biopsy. If the distant metastasis present is near an important organ or greater artery (aorta), it can be a challenge or even life-threatening to attempt a biopsy. Therefore lesions sometimes are left unclassified before treatment.

With the 89-Zirconium-Trastuzumab tracer it is possible to visualise on PET/CT images which lesions binds the tracer and where it can be expected that the treatment will be effective. If there are lesions present where the tracer doesn't bind a different treatment can be chosen (chemotherapy, resection of radiotherapy).

## **Study objective**

Primary Objectives:

Use 89Zr-Trastuzumab to characterise the in vivo biodistribution using PET imaging in the primary tumour and distant metastases.

Compare the uptake in patients with Her2/neu positive breast cancer to patients with HER2/neu negative breast cancer.

Secondary Objectives:

Compare the 89Zirconium tracer uptake within the primary tumour and metastases with lesions visualised on the 18F-FDG PET/ CT.

Relate circulating HER2/neu (serum HER2) concentration to 89Zr-Trastuzumab uptake in the tumour.

## **Study design**

Patients with stadium II/III breast cancer with distant metastases visible on 18F-FDG PET/CT will be asked to participate in this study. A total of 12 patients will be included (8 with and 4 without HER2/neu amplification or overexpression).

Two hours before administration of the tracer venous blood samples will be taken for the measurement of circulating Trastuzumab after administration of a preparation dose Trastuzumab (50 mg intravenously). A total dose of 37 MBq 89-Zirconium-Trastuzumab will be administered.

On the fourth day after administration of the tracer, a new venous blood sample will be taken for the measurement of circulating tracer directly followed by a PET/CT acquisition in hanging prone- and in supine position, followed by a

prone position acquisition on a dedicated breast PET (MAMMI PET). On the sixth day the venous blood sample will be followed solely by a PET/CT acquisition in supine position.

On the Zirconium PET/CT the tracer accumulation will be quantified in all lesions and in normal tissue (e.g. liver, blood pool and kidneys).

### **Study burden and risks**

The participation in this study is not associated with significant risk for the patient or personnel.

The participating patients will acquire a total dose of 20 mSv after the single administration of 37 MBq 89-Zirconium-Trastuzumab and the two low-dose (PET/CT)'s. The radiation dose is comparable to 2 abdominal contrast enhanced CT scans or 3 FDG PET/CT scan acquisitions.

## **Contacts**

### **Public**

Antoni van Leeuwenhoek Ziekenhuis

Plesmanlaan 121  
Amsterdam 1066 CX  
NL

### **Scientific**

Antoni van Leeuwenhoek Ziekenhuis

Plesmanlaan 121  
Amsterdam 1066 CX  
NL

## **Trial sites**

### **Listed location countries**

Netherlands

## **Eligibility criteria**

### **Age**

Adults (18-64 years)  
Elderly (65 years and older)

## Inclusion criteria

Histological confirmed breast cancer (8 with and 4 without HER2/neu overexpression or amplification), with a primary tumour and at least 1 distant metastatic lesion.;Recent diagnostic 18F-FDG PET/CT (less than 1 month old) made at the NKI-AvL.

## Exclusion criteria

A medical condition (e.g. Li-Fraumeni) that would place the patient at unusual risk for development of new malignancies due to radiation.

Concurrent use of investigational drug with unknown biodistribution.

Present pregnancy, or the patient refuses to use an adequate contraception method if pre-menopausal.

Known allergy for murine proteins (present in Trastuzumab).

## Study design

### Design

**Study type:** Observational invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Diagnostic

### Recruitment

NL

Recruitment status: Pending

Start date (anticipated): 01-10-2014

Enrollment: 10

Type: Anticipated

### Medical products/devices used

Product type: Medicine

Brand name: 89-Zirconium-Trastuzumab

|               |                               |
|---------------|-------------------------------|
| Generic name: | Zr89 Trastuzumab              |
| Product type: | Medicine                      |
| Brand name:   | Herceptin-DM1                 |
| Generic name: | Trastuzumab-DM1               |
| Registration: | Yes - NL outside intended use |

## Ethics review

|                    |                  |
|--------------------|------------------|
| Approved WMO       |                  |
| Date:              | 30-09-2014       |
| Application type:  | First submission |
| Review commission: | METC NedMec      |
| Approved WMO       |                  |
| Date:              | 02-02-2015       |
| Application type:  | First submission |
| Review commission: | METC NedMec      |

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

### In other registers

| Register | ID                     |
|----------|------------------------|
| EudraCT  | EUCTR2014-002800-25-NL |
| CCMO     | NL49980.031.14         |